Pharmacokinetics of high dose quercetin – a potential treatment for asthma

Not Applicable

• Conditions: Asthma; Respiratory - Asthma

• Registration Number: ACTRN12622000074796
• Lead Sponsor: eon Huang

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-01-21
• Last Update Posted: 31 January 2022

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1.Age greater than or equal to 18 years
2.Able to provide informed consent
3.Body mass index 18.0 – 35.0 kg/m2

Exclusion Criteria

1.Participants with chronic kidney disease with eGFR < 30
2.Participants with evidence of active or suspected cancer and participants having undergone cancer treatment including resection, radiation therapy or chemotherapy within the last 2 years (participants with basal cell carcinoma and squamous cell carcinoma are allowed)
3.Participation in a separate clinical or device trial within 4 weeks of screening
4.Participants currently taking cyclosporine, pravastatin, fexofenadine, and/or midazolam
5.Pregnant or lactating women
6.Allergy to quercetin

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Steady state plasma quercetin level at 6 weeks[After 6 weeks of high dose quercetin supplementation]

Secondary Outcome Measures

Name	Time	Method
Full blood count [Baseline and after 6 weeks of high dose quercetin supplementation];Renal function (assessed by eGFR from blood test)[Baseline and after 6 weeks of high dose quercetin supplementation];Liver function (assessed by liver function test from blood test)[Baseline and after 6 weeks of high dose quercetin supplementation];Serum C-reactive protein[Baseline and after 6 weeks of high dose quercetin supplementation];Adherence to supplementation (assessed by returned capsule count at end of study)[After 6 weeks of high dose quercetin supplementation];Adverse events (e.g. gastro-intestinal discomfort, nausea, anorexia, headache, etc) reported <br> and documented by participants on diary cards[After 6 weeks of high dose quercetin supplementation]